Jeil Pharmaceutical Achieves 'Phase 1 Anticancer Drug' Result One Year After Establishing New Drug Development Subsidiary

Jeil Pharmaceutical Exterior (Photo by Jeil Pharmaceutical)

Jeil Pharmaceutical's investment in new drug development is beginning to show tangible results. Onconic Therapeutics, a new drug development subsidiary established in May last year, recently presented the results of a Phase 1 clinical trial of the dual-inhibitor anticancer drug ‘JPI-547’ at the American Society of Clinical Oncology (ASCO), demonstrating achievements within just one year of its founding.

JPI-547 is a dual-inhibitor targeted anticancer agent that simultaneously inhibits PARP and tankyrase. It suppresses both the signaling molecules involved in cancer cell growth and the DNA damage repair enzymes in cancer cells. In March, it was designated as an orphan drug by the U.S. Food and Drug Administration (FDA) for pancreatic cancer, enabling benefits such as tax reductions, exemption from application fees, and seven years of market exclusivity upon approval.

The reflux esophagitis treatment ‘JP-1366’ is being developed as an advanced new drug compared to existing proton pump inhibitors (PPIs). It is about to enter Phase 3 clinical trials in Korea and Europe. Additionally, Jeil Pharmaceutical’s Central Research Institute is conducting global-targeted research on innovative new drug candidates it discovered, including the stroke treatment ‘JPI-289’ and the diabetes treatment ‘JP-2266’.

This content was produced with the assistance of AI translation services.